Latanoprost Eg

Latanoprost, the active ingredient in Latanoprost Eg, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure by enhancing aqueous humor outflow, and is indicated for the management of open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Latanoprost Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across markets. Our distribution network includes major eye‑care centres and procurement teams, with dedicated support for product registration and logistics.

Latanoprost is a prostaglandin analog used to manage conditions that involve elevated intra‑ocular pressure.

- Open-angle glaucoma: lowers intra‑ocular pressure to slow disease progression. - Ocular hypertension: reduces intra‑ocular pressure to prevent development of glaucoma. - Secondary glaucoma: decreases pressure in certain secondary forms, aiding visual field preservation.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eyelash growth: increased length and thickness. - Eye irritation: transient burning or stinging. - Blurred vision: temporary visual disturbance.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or anaphylaxis. - Uveitis: inflammation of the uveal tract. - Macular edema: fluid accumulation affecting central vision.

Before using Latanoprost, consider the following precautions.

- Monitor intra‑ocular pressure: regular measurements are required. - Assess for ocular infection: avoid use if active infection is present. - Avoid contact lenses: discontinue use 15 minutes before and after instillation. - Caution in corneal disease: evaluate risk in patients with corneal abnormalities. - Store at room temperature: keep bottle in original packaging, protect from light and moisture.

Latanoprost may interact with other ophthalmic or systemic agents.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops: may reduce Latanoprost efficacy. - Combination with other prostaglandin analogs: risk of additive ocular side effects.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive intra‑ocular pressure lowering effect. - Carbonic anhydrase inhibitors: enhanced pressure reduction. - Systemic prostaglandin analogs: potential systemic effects requiring observation.